Ülke: Kanada
Dil: İngilizce
Kaynak: Health Canada
CASPOFUNGIN (CASPOFUNGIN ACETATE)
JUNO PHARMACEUTICALS CORP.
J02AX04
CASPOFUNGIN
70MG
POWDER FOR SOLUTION
CASPOFUNGIN (CASPOFUNGIN ACETATE) 70MG
INTRAVENOUS
15G/50G
Prescription
ECHINOCANDINS
Active ingredient group (AIG) number: 0144763002; AHFS:
APPROVED
2017-04-18
_Caspofungin for Injection_ _Page 1 of 50_ PRODUCT MONOGRAPH Pr . CASPOFUNGIN FOR INJECTION 50 mg/vial, 70 mg/vial Caspofungin (as caspofungin acetate) Antifungal JUNO PHARMACEUTICALS CORP. 402-2233 Argentia Road Mississauga, ON L5N 2X7 DATE OF PREPARATION: May 21, 2021 SUBMISSION CONTROL NUMBER: 247611 _Caspofungin for Injection_ _Page 2 of 50_ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ...................................................... 3 SUMMARY PRODUCT INFORMATION ................................................................... 3 DESCRIPTION ............................................................................................................ 3 INDICATIONS AND CLINICAL USE......................................................................... 3 CONTRAINDICATIONS............................................................................................. 4 WARNINGS AND PRECAUTIONS ............................................................................ 4 ADVERSE REACTIONS ............................................................................................. 7 DRUG INTERACTIONS ............................................................................................21 DOSAGE AND ADMINISTRATION..........................................................................22 OVERDOSAGE..........................................................................................................28 ACTION AND CLINICAL PHARMACOLOGY .........................................................29 STORAGE AND STABILITY.....................................................................................30 DOSAGE FORMS, COMPOSITION AND PACKAGING ...........................................30 PART II: SCIENTIFIC INFORMATION........................................................................... 32 PHARMACEUTICAL INFORMATION .....................................................................32 CLINICAL TRIALS................................................................................... Belgenin tamamını okuyun